PHARMACY **BENEFACT**

Number 1052 • August 2022

A BULLETIN FOR PHARMACY SERVICE PROVIDERS FROM ALBERTA BLUE CROSS®

Reminder of Maximum Allowable Cost (MAC) pricing reinstatement to combination Angiotension-Converting Enzyme (ACE) inhibitor groupings

Product supply shortage addressed for the Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has confirmed that supply of the *Alberta Drug Beneft List (ADBL)* listed Lisinopril/HCTZ 1 x 20 mg/25 mg tablet products are now available.

As these products set the maximum allowable price for the combination Angiotension-Converting Enzyme (ACE) Inhibitor Maximum Allowable Cost (MAC) grouping, and were unavailable, the MAC price policy was suspended on December 22, 2019. As a result of confirmed availability, the MAC price policy was reapplied effective May 26, 2022.

As a reminder, a MAC grouping is a grouping of drug products listed on the *ABDL* as being subject to a maximum price. Note that a MAC grouping may also include one or more groupings of interchangeable drugs.

Combination ACE inhibitor products subject to MAC and/or Least Cost Alternative (LCA) pricing on the ADBL are listed below.

Active ingredient	Strength or form	LCA or MAC price	
CILAZAPRIL/ HYDROCHLOROTHIAZIDE	5 MG / 12.5 MG ORAL TABLET		
ENALAPRIL MALEATE/ HYDROCHLOROTHIAZIDE	5 MG / 12.5 MG & 10 MG / 25 MG ORAL TABLET	\$0.2503	MAC pricing has been applied based on the LCA price for Lisinopril / HCTZ 1 x 20 mg / 25 mg tablet.
PERINDOPRIL ERBUMINE/ INDAPAMIDE HEMIHYDRATE	4 MG / 1.25 MG & 8 MG / 2.5 MG ORAL TABLET		
QUINAPRIL/ HYDROCHLOROTHIAZIDE	10 MG / 12.5 MG, 20 MG / 12.5 MG & 20 MG / 25 MG ORAL TABLET		
RAMIPRIL/ HYDROCHLOROTHIAZIDE	2.5 MG / 12.5 MG, 5 MG / 12.5 MG, 5 MG / 25 MG, 10 MG / 12.5 MG & 10 MG / 25 MG ORAL TABLET		
LISINOPRIL/ HYDROCHLOROTHIAZIDE	10 MG / 12.5 MG, 20 MG / 12.5 MG & 20 MG / 25 MG ORAL TABLET	These products are not affected by MAC pricing. LCA pricing will continue to apply.	

Please refer to the online *interactive Drug Benefit List (iDBL)* at **ab.bluecross.ca/dbl/idbl_main1.php** for a full listing of combination ACE Inhibitor products. Please note that the *iDBL* is a near real-time application, and as such, contains the most up-to-date information.







continued from previous page

Product supply shortage addressed for *Alberta Drug* Benefit List (ADBL)

Alberta Blue Cross[®] has been advised by Actavis Pharma Company that the shortage for Act Dextroamphetamine SR 10 mg Sustained-Release Capsule (DIN 02448319) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **September 23, 2022**. The following grouping was removed from the Critical Supply Product List **August 24, 2022**.

DEXTROAMPHETAMINE SULFATE

00002448319	ACT DEXTROAMPHETAMINE SR	АРН	\$ 0.8096
00001924559	DEXEDRINE	PAL	\$ 0.9519

Temporary benefit added to the *Alberta Drug Benefit List* (ADBL)

Due to the unavailability of Diphenhydramine HCl 50 mg/ml Injection (DIN 00596612) manufactured by Sandoz Canada Inc., Diphenhydramine Hydrochloride 50 mg/ml Injection (DIN 02369567) manufactured by Fresenius Kabi Canada will be considered a temporary benefit for the *Alberta Drug Beneft List (ADBL)*. This grouping was added to the Critical Supply Product List **August 23, 2022**.

As of **August 23**, **2022**, all claims for Diphenhydramine Hydrochloride 50 mg/ml Injection (DIN 02369567) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at **ab.bluecross.ca/providers/pharmacy-home.php**.

If this situation continues to be a long-term matter, then these products are subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics and must be approved by the Minister of Health for addition to the *ADBL* in order to remain as a benefit.

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area) 403-294-4041 (Calgary and area) 1-800-361-9632 (toll free) FAX 780-498-8406 (Edmonton and area) FAX 1-877-305-9911 (toll free)



Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php



**The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. *† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.1052 2022/08